Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 1.00 |
| ▸ | CXCL8 | P10145 | 5/20 | 0.68 |
| ▸ | TTR | P02766 | 3/20 | 0.68 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.68 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.68 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.68 |
| ▸ | ALB | P02768 | 1/20 | 0.68 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.68 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.68 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.68 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.68 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.68 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.68 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.68 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11560663 | 0.90 | PTGS2 (1.00) | PTGS2CXCL8TTRAKR1B10UGT1A9 | |
| SCHEMBL15344042 | 0.87 | PTGS2 (0.77) | PTGS2CXCL8TTRAKR1B10UGT1A9 | |
| SCHEMBL7166134 | 0.87 | PTGS2 (0.77) | PTGS2CXCL8TTRAKR1B10UGT1A9 | |
| SCHEMBL11563957 | 0.86 | PTGS2 (0.75) | PTGS2CXCL8TTRAKR1B10UGT1A9 | |
| SCHEMBL7162418 | 0.86 | PTGS2 (0.75) | PTGS2CXCL8TTRAKR1B10UGT1A9 | |
| SCHEMBL7164856 | 0.85 | PTGS2 (0.83) | PTGS2CXCL8TTRAKR1B10UGT1A9 | |
| SCHEMBL15369143 | 0.84 | PTGS2 (0.73) | PTGS2CXCL8TTRAKR1B10UGT1A9 | |
| SCHEMBL11564340 | 0.84 | PTGS2 (0.73) | PTGS2CXCL8TTRAKR1B10UGT1A9 | |
| SCHEMBL11567028 | 0.84 | PTGS2 (0.73) | PTGS2CXCL8TTRAKR1B10UGT1A9 | |
| SCHEMBL1032123 | 0.83 | PTGS2 (0.71) | PTGS2CXCL8TTRAKR1B10UGT1A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016046674-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MODERATE TO SEVERE PAIN | MOHAN M ALAPATI (IN) | 2016-03-31 | — | — | WO | disclosed |
| US-8557986-B2 | Method of producing polysaccharide derivatives | SEIKAGAKU CORPORATION (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20110083991-A1 | HYALURONIC ACID DERIVATIVE AND DRUG CONTAINING THE SAME | SEIKAGAKU CORPORATION (JP) | 2011-04-14 | — | — | US | disclosed |
| US-7879817-B2 | Non-steroidal anti-inflammatory drugs bound to hyaluronic acid through a covalent bond via a spacer having a biodegradable region and disease-modifying anti-rheumatic drugs; salicylic acid, aspirin, mefenamic acid, tolfenamic acid; arthritis, suppress inflammation and pain; parenteral, topical | SEIKAGAKU CORPORATION (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20090104678-A1 | METHOD OF PRODUCING POLYSACCHARIDE DERIVATIVES | SEIKAGAKU CORPORATION (JP) | 2009-04-23 | — | — | US | disclosed |
| US-20080221062-A1 | Hyaluronic Acid Derivative and Drug Containing the Same | SEIKAGAKU CORPORATION (JP) | 2008-09-11 | — | — | US | disclosed |
| EP-1242069-B1 | ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES | EXOCELL INC (US) | 2005-06-29 | — | — | EP | disclosed |
| US-6552077-B2 | Kidney disorders | EXOCELL, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1242069-A2 | ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES | EXOCELL, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6355680-B1 | BLOCKING REACTION OF GLUCOSE AND ALBUMIN | EXOCELL, INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | EXOCELL, INC. | 2001-10-25 | — | — | US | disclosed |
| WO-2001003684-A2 | ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES | EXOCELL, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
| US-4173577-A | ANTICOAGULANTS; ANTIINFLAMMATORY AGENTS; ANTIPYRETICS; ANALGESICS | CIBA-GEIGY CORPORATION (US) | 1979-11-06 | — | — | US | disclosed |
| US-4092430-A | ANTICOAGULANTS, ANALGESTIC, ANTIPYRETIC ACTIVITY | CIBA-GEIGY CORPORATION (US) | 1978-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | ALB, AGER, TTR | PTGS2 2067/4885CXCL8 3032/4885TTR 3/4885 |
| US-20090104678-A1 | METHOD OF PRODUCING POLYSACCHARIDE DERIVATIVES | RCC1, FOXM1, C1S | PTGS2 2647/4885CXCL8 1312/4885TTR 3661/4885 |
| US-20080221062-A1 | Hyaluronic Acid Derivative and Drug Containing the Same | CD44, HCAR1, MMP1 | PTGS2 125/4885CXCL8 206/4885TTR 2226/4885 |
| US-20110083991-A1 | HYALURONIC ACID DERIVATIVE AND DRUG CONTAINING THE SAME | CD44, HCAR1, MMP1 | PTGS2 125/4885CXCL8 206/4885TTR 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.